Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about HCW Biologics Inc.
HCW Biologics Inc. News
HCW Biologics Inc. Quantitative Score
About HCW Biologics Inc.
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
HCW Biologics Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
HCW Biologics Inc. Financials
Table Compare
Compare HCWB metrics with: | |||
|---|---|---|---|
Earnings & Growth | HCWB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | HCWB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | HCWB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | HCWB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
HCW Biologics Inc. Income
HCW Biologics Inc. Balance Sheet
HCW Biologics Inc. Cash Flow
HCW Biologics Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
HCW Biologics Inc. Executives
| Name | Role |
|---|---|
| Dr. Hing C. Wong Ph.D. | Founder, Chief Executive Officer, Director & Secretary |
| Dr. Peter Rhode Ph.D. | Chief Scientific Officer & Vice President of Clinical Operations |
| Mr. Lee D. Flowers | Senior Vice President of Business Development |
| Ms. Nicole Valdivieso Esq. | Vice President of Legal Affairs |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Hing C. Wong Ph.D. | Founder, Chief Executive Officer, Director & Secretary | 1954 | 368.19K | |
| Dr. Peter Rhode Ph.D. | Chief Scientific Officer & Vice President of Clinical Operations | 1958 | 261.67K | |
| Mr. Lee D. Flowers | Senior Vice President of Business Development | Male | 1946 | -- |
| Ms. Nicole Valdivieso Esq. | Vice President of Legal Affairs | Female | -- |
HCW Biologics Inc. Insider Trades
| Date | 16 May |
| Name | Wong Hing C |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 8054 |
| Date | 16 May |
| Name | Winer Gary M |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 1342 |
| Date | 16 May |
| Name | GARRETT SCOTT T |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 13423 |
| Date | 8 May |
| Name | Winer Gary M |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2308 |
| Date | 7 May |
| Name | Winer Gary M |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 1154 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 16 May | Wong Hing C | Chief Executive Officer | Acquired | P-Purchase | 8054 |
| 16 May | Winer Gary M | Director | Acquired | P-Purchase | 1342 |
| 16 May | GARRETT SCOTT T | Director | Acquired | P-Purchase | 13423 |
| 8 May | Winer Gary M | Director | Acquired | P-Purchase | 2308 |
| 7 May | Winer Gary M | Director | Acquired | P-Purchase | 1154 |